Antibody Market Outlook for 2024 to 2034

The global antibody market size is estimated to be worth around 266.83 billion in 2024. The total market value of the antibodies sector is anticipated to increase at a CAGR of 8.1% from 2024 to 2034. Furthermore, it is anticipated that the market for antibodies will reach USD 581.42 billion by 2034. The total market growth of the antibodies sector represented in absolute dollars is USD 315 billion.

Report Attribute Details
Antibody Market Size (2024) USD 266.83 billion
Market Anticipated Forecast Value (2034) USD 581.42 billion
Market Projected Growth Rate (2024 to 2034) 8.1% CAGR

Antibody Market Trends & Analysis

  • As the prevalence of autoimmune diseases is on the rise, the demand for antibody drugs has strengthened over the last couple of years. Moreover, the rising application of antibodies in chronic disease treatment is anticipated to create more opportunities for antibody market expansion in the near future.
  • Novel biosimilar antibody manufacturers are slashing their prices to compete with branded antibody manufacturers, especially in the European market. With the expiration of patents of renowned products, a boost in demand for biosimilar antibodies can be expected in upcoming years.

Global Antibody Market Historical Analysis (2019 to 2023) Vs Forecast Outlook (2024 to 2034)

The global antibody market was valued at USD 131.47 billion in 2019. The market overview of antibody drugs progressed at an annual rate of 12.5% between 2019 and 2023. The overall market value was about USD 236.86 billion by 2023.

Attributes Details
Antibody Market Value (2019) USD 131.47 billion
Market Revenue (2023) USD 236.86 billion
Market Historical Growth Rate (CAGR 2019 to 2023) 12.5% CAGR

Growth Opportunities Witnessed by the Global Antibody Market Participants

Research and Development Activities Impact Antibodies Sales Outlook

A surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies is driving growth opportunities for diagnostic specialty antibody suppliers.

In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health's rapid test contract development and manufacturing services.

Rising cases of multiple sclerosis and Parkinson's disease among the older population is a key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, advanced genetic engineering technology, and novel and effective treatments in middle-income countries.

In 2021, Berkeley Lights, a digital cell biology company, joined hands with Genovac, an antibody discovery company, to readily access the right antibodies in the shortest amount of time with the help of modern technology.

Increasing Production of Bio-similar Antibodies is Driving Demand

Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies, and they have very few side effects. In 2020, Johnson and Johnson reported USD 3.75 Billion achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade, generated USD 659 million in 2020.

USA Food and Drug Administration (FDA) approved a biosimilar of Remicade called Avsola in December 2019 and is now eligible for producing biologics products all over the world. Increasing demand for biosimilar antibodies in the treatment of rheumatoid arthritis, along with a high patient acceptance rate, is anticipated to boost the market growth for antibodies.

One of the leaders in prescription medicines, Pfizer, received EU approval for biosimilar antibody therapeutics Amsparity for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020. Elevated new drug approval rates and products in clinical trials in pharmaceutical companies are anticipated to further drive the market in the upcoming years.

Country-wise Insights

The table below mentions the countries that are expected to witness higher growth opportunities in this market.

Regional Market Comparison CAGR (2024 to 2034)
United States 9.6%
Germany 9.4%
United Kingdom 10.1%
India 9.5%
China 6.5%

Advancement in Therapeutics is driving the Market in the United States

The United States therapeutic antibodies market is poised to advance at a rate of 10.1% per year till 2034.

  • Modern healthcare infrastructural facilities and the presence of leading market players in the United States.
  • Autoimmune diseases are the third most common reason for chronic ailments creating a higher demand for antibody drugs in the country.

The Medical Tourism Sector has boosted Antibody Consumption in the United Kingdom

Consumption of antibody products in the United Kingdom is projected to rise at a rate of 10.1% during the forecast years.

  • Higher disease prevalence as well as the United Kingdom citizens’ capacity for spending on cutting-edge medicines.
  • The rapidly improving medical tourism sector of the country is projected to drive the demand for antibodies in the coming days.

Rising Elderly Population Percentage is fueling Antibodies Sales Outlook in China

The antibodies industry in China is projected to thrive at a CAGR of 5.8% through the projected years.

  • Growing awareness about the benefits of antibodies for various medical ailments like rheumatoid arthritis, cancer, and infections.
  • The rising geriatric population and associated ailments are anticipated to drive market growth for antibodies in the upcoming years.

Germany Antibodies Therapeutics Market Size Expanding with Rising Cancer Cases

Sales of antibodies in Germany are anticipated to increase at a rate of 9.4% from 2024 to 2034.

  • A surge in cancer patients is anticipated to drive the demand for antibodies for cancer treatment.
  • Germany's antibody drugs market has strengthened significantly with the presence of top companies, whose products are in great demand worldwide.

Government Funding has Bolstered Antibodies Development and Production in India

Demand for antibodies in India is expected to rise at a rate of 9.5% per year between 2024 and 2034.

  • Rising cases of cancer and cardiovascular diseases along with the development of the healthcare system in the country.
  • Increasing government funding to make the treatment affordable, and increasing consumer spending on healthcare are anticipated to create more opportunities.

Category-wise Insights

Monoclonal Antibodies are More Effective than Polyclonal Antibodies

Based on product type, the monoclonal antibodies market segment is estimated to account for 95% of the market share in 2024.

Attributes Details
Top Product Type or Segment Monoclonal Antibodies
Total Market Share in 2024 95%
  • This segment is bolstering in response to the increasing cases of rheumatoid arthritis, psoriasis, and asthma in the geriatric population across the globe.
  • Hospitals are anticipated to remain the dominant end user of monoclonal antibodies on account of rising cases of various types of chronic ailments.

Recombinant Antibodies are Primarily Used for Cancer Treatment

Based on disease indication, the use of antibodies for treating cancer is expected to account for 57% of the total sales in 2024.

Attributes Details
Top Disease Indication Type or Segment Cancer
Total Market Share in 2024 57%
  • The rising prevalence of non-Hodgkin lymphoma and other types of cancer has fuelled the demand for cancer antibodies for developing non-invasive and safe treatment options.
  • With the focus on cancer research increasing, the antibodies sales outlook for the upcoming decade is anticipated to remain positive.

Competitive Landscape for Antibody Market

Leading market players are working towards developing new antibodies to remain competitive in the present market. They are also researching to create long-acting antibody drugs to reduce healthcare costs and attract chronic patients.

In order to gain a competitive edge in the antibody testing market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic mergers and acquisitions for portfolio expansion are in the cards as well.

Startups Should Concentrate on Increasing the Scope of Their Research to Promote Innovation

Future market players should concentrate on acquiring additional money through financing rounds to broaden their research and company scope. New businesses are looking into how to leverage cutting-edge technologies to streamline the creation of therapeutic antibodies, including nanobodies and monoclonal antibodies.

  • Great Bay Bio (GBB), a start-up with headquarters in Hong Kong, declared in September 2022 that it had successfully raised USD 15 million in its Pre-series B investment round. The financing is to be put to use by the business to quicken the creation of bioprocessing platforms that are powered by artificial intelligence (AI) in order to enhance the CMC process for a variety of biological pharmaceuticals, such as monoclonal antibodies and fusion proteins.
  • Capstan Therapeutics, a startup with the goal of creating treatments for conditions with unmet medical needs, declared its launch in September 2022 and provided USD 165 million for in-vivo cell engineering. The business is creating in-vivo CAR treatments, which allow for cell engineering while the patient is still receiving treatment.
  • Versant Ventures, a well-known investor in biotechnology startups, announced a new relationship with AbCellera, a business specializing in antibody development, in July 2022. Through this collaboration, Versant has significantly sped up the research and development process by supplying start-ups with antibodies from AbCellera that are tailored to their target disease.

Recent Developments in the Global Antibody Market

  • Research: Investigational Oral Treatment

On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment iptacopan, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that during 12 weeks of iptacopan monotherapy treatment, no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.

  • Acquisition: Johnson & Johnson and Momenta Pharmaceuticals Inc.

In August 2020, Johnson & Johnson entered into a final agreement to acquire Momenta Pharmaceuticals Inc. for around USD 6.5 Billion. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.

The acquisition may allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth opportunities through expansion into autoantibody-driven disease.

  • Partnership: Sanofi and IGM Biosciences

Leading pharmaceutical company Sanofi announced in March 2022 that it will collaborate with IGM Biosciences to research, produce, and market six novel immunoglobulin M antibody agonists. Sanofi has agreed to approximately USD 6 billion in possible milestone payments through this agreement.

Key Players Profiled in the Antibody Market Report

  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.

Key Coverage in the Antibody Market Report

  • Adjacent study on research antibodies & reagents market.
  • Comparative analysis of antibody vs. antigen market.
  • Antibody market potential in African nations.

Antibody Market Report Scope

Attribute Details
Estimated Market Size (2024) USD 266.83 billion
Projected Market Size (2034) USD 581.42 billion
Anticipated Growth Rate (2024 to 2034) 8.1%
Forecast Period 2024 to 2034
Historical Data Available for 2019 to 2023
Market Analysis USD million or billion for Value and Units for Volume
Key Regions Covered North America; Latin America; Europe; Middle East & Africa (MEA); East Asia; South Asia and Oceania
Key Countries Covered United States, Canada, Brazil, Mexico, Germany, Spain, Italy, France, United Kingdom, Russia, China, India, Australia & New Zealand, GCC Countries, and South Africa
Key Segments Covered By Product Type, By Disease Indication, By End Use Verticals, and By Region
Key Companies Profiled Novartis AG; F. Hoffmann-La Roche AG; Johnson & Johnson; Takeda Pharmaceutical Company Limited; Amgen Inc.
Report Coverage Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing Available upon Request

Key Segments Covered by Antibodies Industry Survey Report

By Disease Indication:

  • Cardiovascular Diseases
  • CNS Disorders
  • Cancer
  • Autoimmune Disorders
  • Other Disease Indications

By Product Type:

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Antibody-drug Complexes

By End User:

  • Hospitals
  • Long-term Care Facilities
  • Research Institutes
  • Other End Users

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia and Pacific
  • Middle East and Africa (MEA)

Table of Content

  • 1. Executive Summary
  • 2. Market Overview
  • 3. Market Background
  • 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
  • 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
    • 5.1. Cardiovascular Diseases
    • 5.2. CNS Disorders
    • 5.3. Cancer
    • 5.4. Autoimmune Disorders
  • 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type
    • 6.1. Monoclonal Antibodies
    • 6.2. Polyclonal Antibodies
    • 6.3. Antibody-Drug Complexes
  • 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
    • 7.1. Hospitals
    • 7.2. Long-Term Care Facilities
    • 7.3. Research Institutes
  • 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
    • 8.1. North America
    • 8.2. Latin America
    • 8.3. Western Europe
    • 8.4. Eastern Europe
    • 8.5. South Asia and Pacific
    • 8.6. East Asia
    • 8.7. Middle East and Africa
  • 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
  • 16. Key Countries Market Analysis
  • 17. Market Structure Analysis
  • 18. Competition Analysis
    • 18.1. Novartis AG
    • 18.2. F. Hoffmann-La Roche Ltd.
    • 18.3. Johnson & Johnson Services, Inc
    • 18.4. Takeda Pharmaceutical Company Limited
    • 18.5. Amgen Inc
    • 18.6. Biogen Inc
    • 18.7. Bristol-Myers Squibb Company
    • 18.8. AbbVie Inc
    • 18.9. Sanofi
    • 18.10. Kyowa Kirin Co., Ltd
    • 18.11. Iovance Biotherapeutics, Inc
  • 19. Assumptions & Acronyms Used
  • 20. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034

Table 2: Global Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034

Table 3: Global Market Value (US$ Million) Forecast by Product Type, 2019 to 2034

Table 4: Global Market Value (US$ Million) Forecast by End User, 2019 to 2034

Table 5: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 6: North America Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034

Table 7: North America Market Value (US$ Million) Forecast by Product Type, 2019 to 2034

Table 8: North America Market Value (US$ Million) Forecast by End User, 2019 to 2034

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 10: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034

Table 11: Latin America Market Value (US$ Million) Forecast by Product Type, 2019 to 2034

Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2019 to 2034

Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 14: Western Europe Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034

Table 15: Western Europe Market Value (US$ Million) Forecast by Product Type, 2019 to 2034

Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2019 to 2034

Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 18: Eastern Europe Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034

Table 19: Eastern Europe Market Value (US$ Million) Forecast by Product Type, 2019 to 2034

Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2019 to 2034

Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034

Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Product Type, 2019 to 2034

Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2019 to 2034

Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 26: East Asia Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034

Table 27: East Asia Market Value (US$ Million) Forecast by Product Type, 2019 to 2034

Table 28: East Asia Market Value (US$ Million) Forecast by End User, 2019 to 2034

Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034

Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Product Type, 2019 to 2034

Table 32: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2019 to 2034

List of Figures

Figure 1: Global Market Value (US$ Million) by Disease Indication, 2024 to 2034

Figure 2: Global Market Value (US$ Million) by Product Type, 2024 to 2034

Figure 3: Global Market Value (US$ Million) by End User, 2024 to 2034

Figure 4: Global Market Value (US$ Million) by Region, 2024 to 2034

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034

Figure 8: Global Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034

Figure 9: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034

Figure 10: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034

Figure 11: Global Market Value (US$ Million) Analysis by Product Type, 2019 to 2034

Figure 12: Global Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034

Figure 13: Global Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034

Figure 14: Global Market Value (US$ Million) Analysis by End User, 2019 to 2034

Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2024 to 2034

Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034

Figure 17: Global Market Attractiveness by Disease Indication, 2024 to 2034

Figure 18: Global Market Attractiveness by Product Type, 2024 to 2034

Figure 19: Global Market Attractiveness by End User, 2024 to 2034

Figure 20: Global Market Attractiveness by Region, 2024 to 2034

Figure 21: North America Market Value (US$ Million) by Disease Indication, 2024 to 2034

Figure 22: North America Market Value (US$ Million) by Product Type, 2024 to 2034

Figure 23: North America Market Value (US$ Million) by End User, 2024 to 2034

Figure 24: North America Market Value (US$ Million) by Country, 2024 to 2034

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 28: North America Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034

Figure 29: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034

Figure 30: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034

Figure 31: North America Market Value (US$ Million) Analysis by Product Type, 2019 to 2034

Figure 32: North America Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034

Figure 33: North America Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034

Figure 34: North America Market Value (US$ Million) Analysis by End User, 2019 to 2034

Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034

Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034

Figure 37: North America Market Attractiveness by Disease Indication, 2024 to 2034

Figure 38: North America Market Attractiveness by Product Type, 2024 to 2034

Figure 39: North America Market Attractiveness by End User, 2024 to 2034

Figure 40: North America Market Attractiveness by Country, 2024 to 2034

Figure 41: Latin America Market Value (US$ Million) by Disease Indication, 2024 to 2034

Figure 42: Latin America Market Value (US$ Million) by Product Type, 2024 to 2034

Figure 43: Latin America Market Value (US$ Million) by End User, 2024 to 2034

Figure 44: Latin America Market Value (US$ Million) by Country, 2024 to 2034

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 48: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034

Figure 51: Latin America Market Value (US$ Million) Analysis by Product Type, 2019 to 2034

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034

Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2019 to 2034

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034

Figure 57: Latin America Market Attractiveness by Disease Indication, 2024 to 2034

Figure 58: Latin America Market Attractiveness by Product Type, 2024 to 2034

Figure 59: Latin America Market Attractiveness by End User, 2024 to 2034

Figure 60: Latin America Market Attractiveness by Country, 2024 to 2034

Figure 61: Western Europe Market Value (US$ Million) by Disease Indication, 2024 to 2034

Figure 62: Western Europe Market Value (US$ Million) by Product Type, 2024 to 2034

Figure 63: Western Europe Market Value (US$ Million) by End User, 2024 to 2034

Figure 64: Western Europe Market Value (US$ Million) by Country, 2024 to 2034

Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 68: Western Europe Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034

Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034

Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034

Figure 71: Western Europe Market Value (US$ Million) Analysis by Product Type, 2019 to 2034

Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034

Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034

Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2019 to 2034

Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034

Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034

Figure 77: Western Europe Market Attractiveness by Disease Indication, 2024 to 2034

Figure 78: Western Europe Market Attractiveness by Product Type, 2024 to 2034

Figure 79: Western Europe Market Attractiveness by End User, 2024 to 2034

Figure 80: Western Europe Market Attractiveness by Country, 2024 to 2034

Figure 81: Eastern Europe Market Value (US$ Million) by Disease Indication, 2024 to 2034

Figure 82: Eastern Europe Market Value (US$ Million) by Product Type, 2024 to 2034

Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2024 to 2034

Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034

Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034

Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034

Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034

Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Product Type, 2019 to 2034

Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034

Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034

Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2019 to 2034

Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034

Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034

Figure 97: Eastern Europe Market Attractiveness by Disease Indication, 2024 to 2034

Figure 98: Eastern Europe Market Attractiveness by Product Type, 2024 to 2034

Figure 99: Eastern Europe Market Attractiveness by End User, 2024 to 2034

Figure 100: Eastern Europe Market Attractiveness by Country, 2024 to 2034

Figure 101: South Asia and Pacific Market Value (US$ Million) by Disease Indication, 2024 to 2034

Figure 102: South Asia and Pacific Market Value (US$ Million) by Product Type, 2024 to 2034

Figure 103: South Asia and Pacific Market Value (US$ Million) by End User, 2024 to 2034

Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034

Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034

Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034

Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034

Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Product Type, 2019 to 2034

Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034

Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034

Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2019 to 2034

Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2024 to 2034

Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034

Figure 117: South Asia and Pacific Market Attractiveness by Disease Indication, 2024 to 2034

Figure 118: South Asia and Pacific Market Attractiveness by Product Type, 2024 to 2034

Figure 119: South Asia and Pacific Market Attractiveness by End User, 2024 to 2034

Figure 120: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034

Figure 121: East Asia Market Value (US$ Million) by Disease Indication, 2024 to 2034

Figure 122: East Asia Market Value (US$ Million) by Product Type, 2024 to 2034

Figure 123: East Asia Market Value (US$ Million) by End User, 2024 to 2034

Figure 124: East Asia Market Value (US$ Million) by Country, 2024 to 2034

Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 128: East Asia Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034

Figure 129: East Asia Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034

Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034

Figure 131: East Asia Market Value (US$ Million) Analysis by Product Type, 2019 to 2034

Figure 132: East Asia Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034

Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034

Figure 134: East Asia Market Value (US$ Million) Analysis by End User, 2019 to 2034

Figure 135: East Asia Market Value Share (%) and BPS Analysis by End User, 2024 to 2034

Figure 136: East Asia Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034

Figure 137: East Asia Market Attractiveness by Disease Indication, 2024 to 2034

Figure 138: East Asia Market Attractiveness by Product Type, 2024 to 2034

Figure 139: East Asia Market Attractiveness by End User, 2024 to 2034

Figure 140: East Asia Market Attractiveness by Country, 2024 to 2034

Figure 141: Middle East and Africa Market Value (US$ Million) by Disease Indication, 2024 to 2034

Figure 142: Middle East and Africa Market Value (US$ Million) by Product Type, 2024 to 2034

Figure 143: Middle East and Africa Market Value (US$ Million) by End User, 2024 to 2034

Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034

Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034

Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034

Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034

Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Product Type, 2019 to 2034

Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034

Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034

Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2019 to 2034

Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2024 to 2034

Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034

Figure 157: Middle East and Africa Market Attractiveness by Disease Indication, 2024 to 2034

Figure 158: Middle East and Africa Market Attractiveness by Product Type, 2024 to 2034

Figure 159: Middle East and Africa Market Attractiveness by End User, 2024 to 2034

Figure 160: Middle East and Africa Market Attractiveness by Country, 2024 to 2034

Frequently Asked Questions

How Big is the Global Antibody Market Currently?

The global antibody market is estimated to be around USD 266.83 billion in 2024.

What is the Growth Outlook of the Antibody Market?

The global antibody market is to grow at 8.1% during the forecast period.

What is the projected Value of Antibody Market by 2034?

The global antibody market is predicted to be valued at USD 581.42 billion by 2034.

What was the Historical Size of the Antibody Market?

The global antibody market was valued at USD 131.47 billion in 2019.

Which Regional Antibody Market has the Highest Growth Potential?

The United Kingdom to witness 10.1% CAGR in sales of antibodies through 2034.

Explore Life Science & Biotechnology Insights

Future Market Insights

Antibody Market